PRINCETON, N.J., April 28, 2008 (PRIME NEWSWIRE) -- Barrier Therapeutics, Inc. (Nasdaq:BTRX), a pharmaceutical company that develops and markets dermatology products, today announced that executive management will participate in the Deutsche Bank 33rd Annual Health Care Conference to be held May 5 through May 7, 2008 at The Intercontinental Boston. Mr. Al Altomari, Chief Executive Officer, is scheduled to present at 4:50 p.m. Eastern Time on Tuesday, May 6, 2008.
The presentation will be available via a live webcast and can be accessed through the Investor Relations section of Barrier Therapeutics' corporate website at: www.barriertherapeutics.com. An archive of the presentation will be available for replay for 90 days.
About Barrier Therapeutics
Barrier Therapeutics, Inc. is a pharmaceutical company focused on the development and commercialization of products in the field of dermatology. Barrier Therapeutics currently markets three pharmaceutical products in the United States: Xolegel(r) (ketoconazole, USP) Gel, 2%, for seborrheic dermatitis; Vusion(r) (0.25% miconazole nitrate, 15% zinc oxide, 81.35% white petrolatum) Ointment, for diaper dermatitis complicated by documented candidiasis; and Solage(r) (mequinol 2.0%, tretinoin 0.01%) Topical Solution, for solar lentigines. Barrier Therapeutics has other product candidates in various stages of clinical development for the treatment of a range of dermatological conditions, including onychomycosis, psoriasis, acne, skin allergies, and superficial fungal infections. The company is headquartered in Princeton, New Jersey and has a wholly-owned subsidiary in Geel, Belgium. More information about Barrier Therapeutics can be found on its corporate website at: www.barriertherapeutics.com.
Xolegel, Vusion and Solage are trademarks of Barrier Therapeutics, Inc.